Skip To Main Content
This website is intended exclusively for the healthcare professionals residing and/or working in Thailand.
Campus
  • Science
Campus
  • Science
  • Article
  • Source: Campus Sanofi

WHO recommended composition of influenza virus vaccines for use in the Northern hemisphere 2023-2024

Strain The 2023 Southern hemisphere1 The 2023-2024 Northern hemisphere.2
A/H1N1 an A/Sydney/5/2021 (H1N1)pdm09-like virus an A/Victoria/4897/2022 (H1N1)pdm09-like virus
A/H3N2  an A/Darwin/9/2021 (H3N2)-like virus an A/Darwin/9/2021 (H3N2)-like virus
B/Victoria  a B/Austria/1359417/2021 (B/Victoria lineage)-like virus a B/Austria/1359417/2021 (B/Victoria lineage)-like virus
B/Yamagata  a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus

  1. https://www.who.int/influenza/vaccines/virus/recommendations/2023_south/en/

  2. https://www.who.int/influenza/vaccines/virus/recommendations/2023-24_north/en/

Get a copy of this article for offline reading:

Download

Burden of Influenza Hospitalization among High-Risk Groups in the United States

Burden of Influenza Hospitalization among High-Risk Groups in the United States

Learn more
Enhanced Passive Safety Surveillance of High-Dose and Standard-Dose Quadrivalent Inactivated Split-Virion Influenza Vaccines in Germany and Finland During the Influenza Season 2021/22

Enhanced Passive Safety Surveillance of High-Dose and Standard-Dose Quadrivalent Inactivated Split-Virion Influenza Vaccines in Germany and Finland During the Influenza Season 2021/22

Learn more
Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine in Older Adults in Taiwan: A Phase Iii, Randomized, Multi-Center Study

Immunogenicity and Safety of High-Dose Quadrivalent Influenza Vaccine in Older Adults in Taiwan: A Phase Iii, Randomized, Multi-Center Study

Learn more
MAT-TH-2300676-v1.0(06/23)